Risikoen for sådanne reaktioner synes at være størst tidligt i behandlingen, idet de fleste hudreaktioner forekommer inden for behandlingens første måned.
Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment.